Codexis public offering of common stock
Analysis based on 9 articles · First reported Jul 23, 2026 · Last updated Jul 24, 2026
The offering dilutes existing shareholders but provides Codexis with capital to fund operations and growth. The stock price may face downward pressure due to the dilutive effect, but the capital infusion supports the company's enzymatic solutions business.
Codexis, Inc. (Nasdaq: CDXS) announced on July 23, 2026, the pricing of an underwritten public offering of 16,666,667 shares of its common stock at $1.50 per share, with expected net proceeds of approximately $23.1 million. The offering is expected to close on July 27, 2026. Codexis granted underwriters a 30-day option to purchase up to an additional 2,500,000 shares. The company intends to use the net proceeds for working capital and general corporate purposes, including research, development, and business activities. Piper Sandler Companies and Cantor Fitzgerald are acting as joint bookrunning managers, with Craig-Hallum Capital Group as co-manager. The offering is made under an effective registration statement filed with the United States — United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard